Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic therapies for...

Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve...

In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs) using Gene Writers encapsulated in proprietary lipid...

BOSTON, Nov. 18, 2024 /PRNewswire/ -- Indigo Ag and Truterra today announced a strategic collaboration aimed at simplifying, expanding...

A single intravenous administration of Gene Writer™ resulted in an estimated 79% hepatocyte genomic editing with an average of 84% of...

Since stepping down as CEO of Alnylam Pharmaceuticals three years ago, John Maraganore has lent his talents widely, joining the boards of...

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein...

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who...

Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to...